Liposomal irinotecan+5-FU/LV+Lenvatinib

Phase 2Small molecule

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Liposomal irinotecan+5-FU/LV+Lenvatinib is one of 14 small molecule programs targeting Phase II Clinical Study. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase II Clinical StudyNot yet recruiting

Phase II Clinical StudyPhase 2

Not yet recruiting

Competition

Competitive Landscape

15 competitors in Phase II Clinical Study

#DrugCompanyPhaseTrials

UBT251

Novo Nordisk

Phase 2

1 2

Mfolfox6

Roche

Phase 2

1 3

HLX43

Shanghai Henlius Biotech

Phase 2

3 4

HLX10

Shanghai Henlius Biotech

Phase 2

1 5

AK112

SSummit Therapeutics

Phase 2

1 6

AK104

AAkeso

Phase 2

1 7

Befotertinib

BBetta Pharmaceuticals Co., Ltd.

Phase 2

1 8

JSKN016

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2

1 9

HLX07

Shanghai Henlius Biotech

Phase 2

2 10

LTC004

LLetolab

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Not yet recruiting

Phase II Clinical Study

NCT07099794

Clinical

Trials by Indication[1]

Phase II Clinical Study1 trial

A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen

Not yet recruiting·—·Phase 2·NCT07099794·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Liposomal irinotecan+5-FU/LV+Lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Liposomal irinotecan+5-FU/LV+Lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Liposomal irinotecan+5-FU/LV+Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Institute and Hospital, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Liposomal irinotecan+5-FU/LV+Lenvatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Phase II Clinical Study1 trial

References

Drug Info

Quick Facts

Related News